CHEMORADIOTHERAPY OF BRAIN GLIOBLASTOMA MULTIFORME


Cite item

Full Text

Abstract

The article presents the results of study that based on assessment of median time to progression (MTTP) and overall survival has examined the potentials of different forms of chemoradiotherapy (CRT) in the complex treatment of brain glioblastoma. The study has included 127 patients with glioblastoma multiforme. All patients underwent surgery or biopsy of the tumor, and subsequently, received post-operative radiation therapy (RT) or chemoradiotherapy. Group 1 received only radiotherapy, Group 2 - Lomustin (CCNU) and hydroxycarbamid, and Group 3 - temozolomide (TMZ). On completing of CRT, chemotherapy was continued. A statistically significant increase of MTTP was observed in group of patients receiving combined CRT with TMZ.

References

  1. American Cancer Society: Cancer Facts and Figures 2010. Atlanta, Ga: American Cancer Society, 2010.
  2. Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
  3. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30(9):907-11.
  4. Halperin EC, Burger PC, Bullard DE. The fallacy of the localized supratentorial malignant glioma. Int J Radiat Oncol Biol Phys 1988;15(2):505-09.
  5. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 80-01 (BTCG 80-01). J Neurosurg. 1989;71:1-9.
  6. Смолин А.В., Конев А.В., Серяков А.П. и др. Локализация рецидивов после лучевой терапии при глиобластомах головного мозга. Материалы науч. практ. конф. "Роль Московской гошпитали в становлении и развитии отечественного государственного больничного дела, медицинского образования и науки". ГВКГ им. Н.Н. Бурденко. М., 2007. Т. II. С. 226.
  7. Chan JL, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002;20(6):1635-42.
  8. Werner-Wasik M, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-82. Cancer 1996;77(8):1535-43.
  9. Chang CH. Hyperbaric oxygen and radiation therapy in the management of glioblastoma. Natl Cancer Inst Monogr 1977;46:163-69.
  10. Miralbell R, et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol1999;17(10):3143-49.
  11. Phillips TL, Levin VA, Ahn DK, et al. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center phase II study. Int J Radiat Oncol Biol Phys 1991;21:709-14.
  12. Ford JM, et al. Comparison of survival of patients in the phase I study of motexafin gadolinium (MGd) with radiation therapy (RT) for glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG RPA glioma database. Proc Am Soc Clin Oncol 2003;22:425.
  13. Dandy WE. Removal of right cerebral hemisphere for certain tumors with hemiplegia. JAMA 1928;90:823-25.
  14. Fine А, Dear KBG, Loefler JS, et al. Meta-Analysis of Radiation Therapy with and without Adjuvant Chemotherapy for Malignant Gliomas in Adults. Cancer 1993;71(8):2585-97, 15.
  15. Fisher B, Won M, MacDonald D, et al. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 2002;53:980-86.
  16. Langer CJ, Ruffer J, Rhodes H, et al. Phase II Radiation Therapy Oncology Group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:113-19.
  17. Coughlin CT, Richmond RC. Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Semin Oncol 1989;16(6):31-43.
  18. Peterson K, Harsh G IV, Fisher PG, et al. Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant gliomas. J Neurooncol 2001;53:27-32.
  19. Glass J, Silverman CL, Axelrod R, et al. Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am J Clin Oncol 1997;20:226-29.
  20. Grossman S, O'Neill A, Grunnet M, et al. Phase III study comparing three cycles of infusional BCNU/Cisplatin followed by radiation with radiation and concurrent BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme (ECOG 2394-SWOG 9508). Proc Am Soc Clin Oncol 2000;612.
  21. Peterson K, Harsh G 4th, Fisher PG, et al. Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma. J Neurooncol 2001;53(1):27-32.
  22. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20(5):1375-82.
  23. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96.
  24. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710.
  25. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-48.
  26. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-45.
  27. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-44.
  28. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
  29. Duda DG, Jain RK, Willett CG. Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007;25:4033-42.
  30. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-48.
  31. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
  32. Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67:3560-64.
  33. Gilbertson RJ, Rich JN. Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007;7:733-36.
  34. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001;61:2413-19.
  35. Baumann F, Bjeljac M, Kollias SS, et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 2004;67:191-200.
  36. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Aug 31 [Epub ahead of print].
  37. Lai A, Nghiemphu P, Green R, et al. Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme, CA J Clin Oncol 27:15s, 2009 (suppl; abstr 2000).
  38. Krishnan S, Rao RD, James CD, et al. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas. Front Biosci 2003;8:11-3.
  39. Chakravarti A, Chakladar A, Delaney MA, et al. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002;62:4307-15.
  40. Prados M, Chang S, Butowski N, et al. Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma. J Clin Oncol 2009;27(4):579-84. Published online 2008 December 15.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies